risperidone has been researched along with Depression, Endogenous in 68 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2 years) inpatients with depressive and anxiety disorders who were treated with risperidone (median doses per day 1." | 9.12 | Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. ( Bares, M; Horacek, J; Kopecek, M; Mohr, P, 2006) |
| "To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone." | 9.12 | Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007) |
| "Seventeen (85%) of 20 patients (13 bipolar, 4 major depressive disorder) showed complete or partial improvement after treatment with risperidone doses ranging from 1 to 6 mg/day (mean = 3." | 9.08 | Risperidone in the treatment of affective illness and obsessive-compulsive disorder. ( Jacobsen, FM, 1995) |
| "This retrospective chart review was conducted to determine the effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone when given in a fee-for-service setting as anti-depressant augmentation agents to patients with treatment-resistant, nonpsychotic major depressive disorder (DSM-IV)." | 7.72 | The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. ( Barbee, JG; Conrad, EJ; Jamhour, NJ, 2004) |
| "In studies of patients with schizophrenia, the atypical antipsychotic risperidone has been shown to be comparable in efficacy to haloperidol and, at dosages of 4 to 8 mg/day, to have a lower rate of extrapyramidal side effects." | 7.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 6.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| "We conducted a post hoc analysis of an international, multicenter, double-blind, 28-week study of 339 patients who met DSM-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder and were randomized to treatment with either olanzapine or risperidone." | 6.19 | Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? ( Andersen, SW; Tollefson, GD, 1999) |
| "2 years) inpatients with depressive and anxiety disorders who were treated with risperidone (median doses per day 1." | 5.12 | Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia. ( Bares, M; Horacek, J; Kopecek, M; Mohr, P, 2006) |
| "To determine the effectiveness of amisulpride on depression in patients with schizophrenia, in comparison to risperidone." | 5.12 | Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial. ( Hwang, MY; Kim, JM; Kim, SW; Lee, JH; Lee, SH; Shin, IS; Yang, SJ; Yoon, BH; Yoon, JS, 2007) |
| "Thirty-six subjects who fulfilled DSM-IV diagnostic criteria for major depressive disorder were given fluvoxamin, 50 or 75 mg/day, with risperidone, 0." | 5.10 | An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. ( Ashby, CR; Hirose, S, 2002) |
| "In 8 patients with major depressive disorder without psychotic features (DSM-IV) who had not responded to an SSRI, risperidone was added to the ongoing SSRI treatment." | 5.09 | Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. ( Nelson, JC; Ostroff, RB, 1999) |
| "Seventeen (85%) of 20 patients (13 bipolar, 4 major depressive disorder) showed complete or partial improvement after treatment with risperidone doses ranging from 1 to 6 mg/day (mean = 3." | 5.08 | Risperidone in the treatment of affective illness and obsessive-compulsive disorder. ( Jacobsen, FM, 1995) |
| "Cariprazine was approved for treating schizophrenia and bipolar disorder, and currently is being evaluated for treating depression in clinical trials in the United States." | 4.98 | Use of cariprazine in psychiatric disorders: A systematic review. ( Chhatlani, A; Farheen, SA; Setty, MJ; Tampi, RR, 2018) |
| "Treatment of acute mania with second-generation antipsychotics has been claimed to involve a lower risk of switch to depression than haloperidol." | 4.89 | Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol. ( Capapey, J; Colom, F; Goikolea, JM; Grande, I; Sanchez-Moreno, J; Torres, I; Undurraga, J; Valentí, M; Vieta, E, 2013) |
| " The receptor profile for risperidone, an atypical antipsychotic with demonstrated efficacy in schizophrenia, is consistent with possible antidepressant activity." | 4.81 | Risperidone: review of its therapeutic utility in depression. ( Myers, JE; Thase, ME, 2001) |
| "This retrospective chart review was conducted to determine the effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone when given in a fee-for-service setting as anti-depressant augmentation agents to patients with treatment-resistant, nonpsychotic major depressive disorder (DSM-IV)." | 3.72 | The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. ( Barbee, JG; Conrad, EJ; Jamhour, NJ, 2004) |
| "In studies of patients with schizophrenia, the atypical antipsychotic risperidone has been shown to be comparable in efficacy to haloperidol and, at dosages of 4 to 8 mg/day, to have a lower rate of extrapyramidal side effects." | 3.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| " A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6." | 2.69 | Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. ( Benkert, O; Hillert, A; Müller, MJ; Müller-Siecheneder, F; Szegedi, A; Wetzel, H, 1998) |
| "Risperidone-treated subjects with a greater degree of acute mood change were both 3." | 2.69 | The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. ( Andersen, SW; Tollefson, GD; Tran, PV, 1999) |
| " Adding risperidone to mirtazapine probably does not necessitate a change of the dosage of either drug, but more extensive investigations are needed." | 2.69 | Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study. ( Doorschot, CH; Loonen, AJ; Oostelbos, MC; Sitsen, JM, 1999) |
| "Risperidone has been shown to be a safe and effective atypical antipsychotic agent." | 2.44 | Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders. ( Bradbury, C; da Silva, TL; McKay, M; Ravindran, AV, 2007) |
| "Schizophrenia is also associated with aggression directed at self and others." | 2.41 | The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| "Olanzapine is a novel antipsychotic agent displaying a unique and pleotrophic pharmacology, which distinguishes it from other existing treatments." | 2.40 | Review of recent clinical studies with olanzapine. ( Kuntz, AJ; Tollefson, GD, 1999) |
| "The effects of neuroleptics on bipolar depression need further study." | 2.39 | Antipsychotics in bipolar disorder. ( Gelenberg, AJ; Hopkins, HS, 1996) |
| " A cumulative dose-response relationship was observed (test for trend, p < 0." | 1.62 | Atypical Antipsychotics Augmentation in Patients with Depressive Disorder and Risk of Subsequent Dementia: A Nationwide Population-Based Cohort Study. ( Ha, TH; Kim, DK; Kim, H; Kim, J; Kim, K; Lee, EM; Lee, H; Lewis, M; Myung, W; Won, HH, 2021) |
| "Morgellons disease is a condition, which is widely discussed on the internet and patients often self-diagnose." | 1.48 | Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes. ( Bewley, A; Mohandas, P; Taylor, R, 2018) |
| "This report shows symptomatic recurrences persisting more than 8 months." | 1.33 | Hallucinogen persisting perception disorder after psilocybin consumption: a case study. ( Abadie, P; Dollfus, S; Espiard, ML; Halbecq, I; Lecardeur, L, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 30 (44.12) | 18.2507 |
| 2000's | 30 (44.12) | 29.6817 |
| 2010's | 7 (10.29) | 24.3611 |
| 2020's | 1 (1.47) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, J | 1 |
| Ha, TH | 1 |
| Kim, K | 1 |
| Lee, EM | 1 |
| Kim, H | 1 |
| Kim, DK | 1 |
| Won, HH | 1 |
| Lewis, M | 1 |
| Lee, H | 1 |
| Myung, W | 1 |
| Mohandas, P | 1 |
| Bewley, A | 1 |
| Taylor, R | 1 |
| Chhatlani, A | 1 |
| Farheen, SA | 1 |
| Setty, MJ | 1 |
| Tampi, RR | 1 |
| Connolly, JG | 1 |
| Toomey, TJ | 1 |
| Schneeweiss, MC | 1 |
| Taoka, H | 1 |
| Hamamura, T | 1 |
| Endo, S | 1 |
| Miyata, S | 1 |
| Toma, K | 1 |
| Ishihara, T | 1 |
| Kuroda, S | 1 |
| Pandina, GJ | 1 |
| Garibaldi, GM | 1 |
| Revicki, DA | 1 |
| Kleinman, L | 1 |
| Turkoz, I | 2 |
| Kujawa, MJ | 1 |
| Mahmoud, RA | 1 |
| Manousaridis, K | 1 |
| Gupta, R | 1 |
| Goikolea, JM | 1 |
| Colom, F | 1 |
| Torres, I | 1 |
| Capapey, J | 1 |
| Valentí, M | 1 |
| Undurraga, J | 1 |
| Grande, I | 1 |
| Sanchez-Moreno, J | 1 |
| Vieta, E | 1 |
| Singh, V | 1 |
| Bowden, CL | 1 |
| Mintz, J | 1 |
| Hirose, S | 1 |
| Ashby, CR | 1 |
| Myers, JE | 1 |
| Thase, ME | 1 |
| Viner, MW | 1 |
| Chen, Y | 1 |
| Bakshi, I | 1 |
| Kamper, P | 1 |
| Sharpley, AL | 1 |
| Bhagwagar, Z | 1 |
| Hafizi, S | 1 |
| Whale, WR | 1 |
| Gijsman, HJ | 1 |
| Cowen, PJ | 1 |
| Hori, K | 1 |
| Oda, T | 1 |
| Tominaga, I | 1 |
| Inada, T | 1 |
| Theodoulou, G | 1 |
| Milner, G | 1 |
| Jumaian, A | 1 |
| Hoeh, N | 1 |
| Gyulai, L | 1 |
| Weintraub, D | 1 |
| Streim, J | 1 |
| Barbee, JG | 1 |
| Conrad, EJ | 1 |
| Jamhour, NJ | 1 |
| Englert, I | 1 |
| Espiard, ML | 1 |
| Lecardeur, L | 1 |
| Abadie, P | 1 |
| Halbecq, I | 1 |
| Dollfus, S | 1 |
| Ahn, MS | 1 |
| Sims, KB | 1 |
| Frazier, JA | 1 |
| Bloch, MH | 1 |
| Landeros-Weisenberger, A | 1 |
| Kelmendi, B | 1 |
| Coric, V | 1 |
| Bracken, MB | 1 |
| Leckman, JF | 1 |
| Cawrse, N | 1 |
| Wilson, S | 1 |
| Williams, M | 1 |
| Burge, T | 1 |
| Kopecek, M | 1 |
| Bares, M | 1 |
| Horacek, J | 1 |
| Mohr, P | 1 |
| Ruhrmann, S | 1 |
| Kissling, W | 1 |
| Lesch, OM | 1 |
| Schmauss, M | 1 |
| Seemann, U | 1 |
| Philipp, M | 1 |
| Ravindran, AV | 1 |
| Bradbury, C | 1 |
| McKay, M | 1 |
| da Silva, TL | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Kim, JM | 1 |
| Lee, SH | 1 |
| Lee, JH | 1 |
| Yoon, BH | 1 |
| Yang, SJ | 1 |
| Hwang, MY | 1 |
| Yoon, JS | 1 |
| Alexopoulos, GS | 1 |
| Canuso, CM | 1 |
| Gharabawi, GM | 1 |
| Bossie, CA | 1 |
| Greenspan, A | 1 |
| Reynolds, C | 1 |
| Carroll, BJ | 1 |
| Dwight, MM | 1 |
| Keck, PE | 4 |
| Stanton, SP | 1 |
| Strakowski, SM | 4 |
| McElroy, SL | 3 |
| Sussman, N | 1 |
| Jones, BD | 1 |
| Purdon, SE | 1 |
| Labelle, A | 1 |
| Finlayson, R | 1 |
| Giakas, WJ | 1 |
| Jacobsen, FM | 1 |
| Wilson, DR | 1 |
| Kizer, DL | 1 |
| Balistreri, TM | 1 |
| Holtman, HM | 1 |
| DePriest, M | 1 |
| Koek, RJ | 1 |
| Kessler, CC | 1 |
| Benazzi, F | 1 |
| Gelenberg, AJ | 1 |
| Hopkins, HS | 1 |
| Negrón, AE | 1 |
| Leiderman, EA | 1 |
| Parkadavil, M | 1 |
| Cienfuegos, A | 1 |
| Javitt, DC | 1 |
| Farah, A | 1 |
| Beale, MD | 1 |
| Kellner, CH | 1 |
| Feeney, DJ | 1 |
| Klykylo, W | 1 |
| Welner, M | 1 |
| Koponen, HJ | 1 |
| Konrad, C | 1 |
| Schormair, C | 1 |
| Eikelmann, B | 1 |
| Telger, K | 1 |
| Bernhard, R | 1 |
| O'Connor, M | 1 |
| Silver, H | 1 |
| Saran, BM | 1 |
| Müller-Siecheneder, F | 1 |
| Müller, MJ | 1 |
| Hillert, A | 2 |
| Szegedi, A | 1 |
| Wetzel, H | 2 |
| Benkert, O | 2 |
| Lane, HY | 2 |
| Chang, WH | 2 |
| Tollefson, GD | 3 |
| Andersen, SW | 2 |
| Kuntz, AJ | 1 |
| Ostroff, RB | 1 |
| Nelson, JC | 1 |
| Chiu, WC | 1 |
| Tran, PV | 1 |
| Loonen, AJ | 1 |
| Doorschot, CH | 1 |
| Oostelbos, MC | 1 |
| Sitsen, JM | 1 |
| Iakovlev, VA | 1 |
| Kaplan, M | 1 |
| Blass, DM | 1 |
| Pearson, VE | 1 |
| Stoll, AL | 1 |
| Haura, G | 1 |
| Hansen, L | 1 |
| Wilkinson, DG | 1 |
| Leslie, DL | 1 |
| Rosenheck, R | 1 |
| Janicak, PG | 1 |
| Davis, JM | 1 |
| Kasckow, JW | 1 |
| Tugrul, K | 1 |
| Dowd, SM | 1 |
| Strong, J | 1 |
| Sharma, RP | 1 |
| Normann, C | 1 |
| Lieb, K | 1 |
| Walden, J | 1 |
| Parker, G | 1 |
| Malhi, G | 1 |
| Weimer, E | 1 |
| Braus, DF | 1 |
| Cavus, I | 1 |
| Thome, J | 1 |
| Maier, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-04-14 | Recruiting | ||
| Open Label Study for the Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder[NCT04775875] | 30 participants (Anticipated) | Interventional | 2020-12-01 | Enrolling by invitation | |||
| Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study[NCT01399450] | Phase 4 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
14 reviews available for risperidone and Depression, Endogenous
| Article | Year |
|---|---|
Use of cariprazine in psychiatric disorders: A systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder; Humans; Piperazines; Risp | 2018 |
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disord | 2013 |
Risperidone: review of its therapeutic utility in depression.
Topics: Animals; Antipsychotic Agents; Depressive Disorder; Humans; Randomized Controlled Trials as Topic; R | 2001 |
Pharmacologic management of psychosis in the elderly: a critical review.
Topics: Aged; Alzheimer Disease; Benzodiazepines; Bipolar Disorder; Clozapine; Depressive Disorder; Drug Adm | 2003 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.
Topics: Animals; Anxiety Disorders; Depressive Disorder; Humans; Mental Disorders; Risperidone | 2007 |
The potential benefits of serotonin receptor-specific agents.
Topics: Antidepressive Agents; Buspirone; Depressive Disorder; Humans; Isoxazoles; Ondansetron; Piperazines; | 1994 |
Antipsychotics in bipolar disorder.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; D | 1996 |
Assessing the effects of atypical antipsychotics on negative symptoms. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Delusions; Depressive Disorder; Hallucinati | 1998 |
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Clozapine; Comorb | 1998 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
Review of recent clinical studies with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Drug Resistance; Humans; Olan | 1999 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; | 2000 |
[Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
Topics: Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Drug Therapy, Combination; Humans; Olanz | 2002 |
14 trials available for risperidone and Depression, Endogenous
| Article | Year |
|---|---|
Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial.
Topics: Adult; Aged; Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder; Disability Evalua | 2010 |
Relative effectiveness of adjunctive risperidone on manic and depressive symptoms in mixed mania.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Depressive Disorder; Diagnostic an | 2013 |
An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Antipsychotic Agents; Depressive Disorder; Dr | 2002 |
Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety; Benzodiazepines; D | 2006 |
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Data Interpretation, Statistical; De | 2007 |
Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Depressive Disorder; Electrocardiography; Endp | 2007 |
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression.
Topics: Aged; Aged, 80 and over; Citalopram; Depressive Disorder; Double-Blind Method; Drug Therapy, Combina | 2008 |
Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Drug Administra | 1995 |
Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depr | 1998 |
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Comorbidity; D | 1999 |
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.
Topics: Adult; Aged; Ambulatory Care; Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, | 1999 |
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cluster Analysis; Cognition Disorders; Depressive Diso | 1999 |
Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Depression; Depressive Disorder | 1999 |
A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Hal | 2001 |
41 other studies available for risperidone and Depression, Endogenous
| Article | Year |
|---|---|
Atypical Antipsychotics Augmentation in Patients with Depressive Disorder and Risk of Subsequent Dementia: A Nationwide Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Dementia; Depressive Disorder; Female | 2021 |
Morgellons disease: experiences of an integrated multidisciplinary dermatology team to achieve positive outcomes.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Antipsychotic | 2018 |
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; B | 2015 |
Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Clozapine; Corpus St | 2008 |
Risperidone-related bilateral cystoid macular oedema.
Topics: Aged; Albuterol; Antipsychotic Agents; Bronchodilator Agents; Depressive Disorder; Female; Fluoresce | 2013 |
Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation.
Topics: Antipsychotic Agents; Depressive Disorder; Dopamine Antagonists; Female; Humans; Middle Aged; Psychi | 2003 |
Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Topics: Administration, Oral; Adult; Antidepressive Agents; Antipsychotic Agents; Cross-Over Studies; Depres | 2003 |
'Awakenings' in demented patients.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Awareness; Cholinesterase Inhibitors; Delusions; Depr | 2003 |
Neuroleptics and family history of Parkinson diseases: case report.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Depressive Disorder; Diagnostic Errors; Female; | 2001 |
The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Depressive Disorder; Dibenzothiazepine | 2004 |
[Diphenhydramin-overdose: anticholinergic symptoms, EEG-findings in the course and drug treatment of a gerontopsychiatric patient].
Topics: Aged; Brain; Cholinergic Antagonists; Dementia; Depressive Disorder; Diphenhydramine; Drug Therapy, | 2004 |
Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depressive Disorder; Diagnosis, Di | 2005 |
Risperidone-induced psychosis and depression in a child with a mitochondrial disorder.
Topics: Adolescent; Depressive Disorder; Epilepsy, Tonic-Clonic; Female; Humans; Mitochondrial Diseases; Moo | 2005 |
Neuroleptic malignant syndrome in the burns patient?
Topics: Antipsychotic Agents; Burns; Depressive Disorder; Fatal Outcome; Female; Fever; Humans; Middle Aged; | 2006 |
'Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation'.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Conflict of Interest; Data Interpretation, Statistic | 2008 |
Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder.
Topics: Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Humans; Isoxazoles; Piperidines; Risper | 1994 |
Risperidone treatment for severe negative symptoms.
Topics: Adult; Antipsychotic Agents; Clonazepam; Depressive Disorder; Drug Therapy, Combination; Humans; Iso | 1994 |
Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Fluoxetine | 1995 |
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Topics: Adult; Age Factors; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Dr | 1995 |
Probable induction of mania by risperidone.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Humans; Male; Risperidone; Serot | 1996 |
Severe depression with risperidone-induced EPS in an elderly schizoaffective patient.
Topics: Aged; Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug- | 1996 |
A naturalistic outcome study of risperidone treatment among hospital patients.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Female; Hospita | 1996 |
Risperidone and ECT combination therapy: a case series.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Combined Modality Therapy; Depressive Disorder; Elect | 1995 |
Risperidone and tardive dyskinesia.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder | 1996 |
Risperidone plus a monoamine oxidase inhibitor for agitated depression crisis.
Topics: Acute Disease; Adult; Antipsychotic Agents; Depressive Disorder; Humans; Male; Monoamine Oxidase Inh | 1996 |
Risperidone in the treatment of psychosis and concomitant buccolinguomasticatory dyskinesia in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Depressive Disorder; Dyskinesia, Drug-Induced; Female | 1997 |
[Risperidone after clozapine in therapy refractory schizoaffective psychosis--a case report].
Topics: Adult; Amitriptyline; Antipsychotic Agents; Clozapine; Depressive Disorder; Dose-Response Relationsh | 1997 |
Can risperidone be antidepressive and also inhibit aggression?
Topics: Aggression; Antipsychotic Agents; Depressive Disorder; Humans; Risperidone | 1997 |
Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.
Topics: Adult; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Paro | 1998 |
Risperidone-induced tardive dyskinesia.
Topics: Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 1998 |
Risperidone monotherapy for psychotic depression unresponsive to other treatments.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Female; Humans; Risperidone; Treatment Outcome | 1998 |
Risperidone monotherapy for mania and depression.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Drug Administration Schedule; Hu | 1999 |
[The new antipsychotic preparation Rispolept (risperidone)].
Topics: Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dopamine Antagonists; Humans; Obsessive | 1999 |
Atypical antipsychotics for treatment of mixed depression and anxiety.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Comorbidity; Depressive Disorder; D | 2000 |
SIADH with multiple antidepressants in a geriatric patient.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Bupropion; Cyclohexanols; Depressive Disorder; Hu | 2000 |
Tranylcypromine plus risperidone for treatment-refractory major depression.
Topics: Antipsychotic Agents; Depressive Disorder; Drug Resistance; Female; Humans; Male; Middle Aged; Monoa | 2000 |
Drug induced akathisia, suicidal ideation and its treatment in the elderly.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Depressive Disorder; Drug Th | 2001 |
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Budgets; Clozapine; Comorbidity; Depressiv | 2001 |
Increased plasma concentration of maprotiline by coadministration of risperidone.
Topics: Adult; Antipsychotic Agents; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Fema | 2002 |
Are the atypical antipsychotic drugs antidepressants?
Topics: Affect; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Depr | 2002 |
Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome--a functional approach.
Topics: Adult; Aged; Antipsychotic Agents; Depressive Disorder; Female; Humans; Isoxazoles; Male; Middle Age | 1992 |